1. Academic Validation
  2. Peiminine triggers ferroptosis to inhibit breast cancer growth through triggering Nrf2 signaling

Peiminine triggers ferroptosis to inhibit breast cancer growth through triggering Nrf2 signaling

  • Tissue Cell. 2024 Feb 4:87:102323. doi: 10.1016/j.tice.2024.102323.
Nian Yi 1 Li Wang 1 Zhongjun Jiang 1 Ge Xu 1 Lihong Li 1 Ya Zhang 1 Yinna Tan 2
Affiliations

Affiliations

  • 1 Thyroid and Breast Surgery, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang City, Hunan Province, PR China.
  • 2 Department of Anesthesiology, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, No. 336 Dongfeng South Road, Zhuhui District, Hengyang City, Hunan Province, PR China. Electronic address: tanyinna0100@163.com.
Abstract

Background: Peiminine (PMI) is an active alkaloid sourced from Fritillaria thunbergii, which has been shown to suppress the development of a variety of tumors. Whereas, the roles and precise mechanism of PMI in breast Cancer (BC) development remain not been clarified.

Methods: The cytotoxic effect of PMI on MCF-10A and BC cell lines (MCF-7 and BT-549) were assessed by MTT and LDH release assay. Cell proliferation was evaluated by EdU staining. Levels of Malondialdehyde (MDA), Reactive Oxygen Species (ROS), glutathione (GSH) activity and iron assay were measured by Enzyme linked immunosorbent assay (ELISA) kits, respectively. Transmission Electron Microscope was performed to observe mitochondrial morphological structure. Immunofluorescence, immunohistochemistry, and western blot were conducted to examine protein levels, respectively. Xenograft model was used to confirm cellular findings.

Results: PMI treatment reduced the viability and enhanced LDH level of MCF-7 and BT-549 cells in a time- and concentration-dependent manner, and further suppressed cell proliferation in vitro and tumor growth in vivo. Subsequently, PMI administration resulted in significant increases of ROS, MDA and iron levels, reduction of GSH activity as well as mitochondrial shrinkage and GPX4 reduction, while all these phenomena could be rescued by ferrostatin-1. Mechanistically, PMI treatment led to promoted Nrf2 expression and its nuclear translocation, as well as it's downstream protein HO-1 and NQO1 expressions. Notably, ML-385, a Nrf2 specific inhibitor, greatly reversed the anti-tumor effects and pro-ferroptosis role of PMI in BC cells.

Conclusion: Taking these finding together, PMI could stimulate Ferroptosis to inhibit BC tumor growth by activating Nrf2-HO-1 signaling pathway.

Keywords

Breast cancer; Ferroptosis; Peiminine; Proliferation.

Figures
Products